Infectious Diseases and Clinical Microbiology

Uzm. Dr. Gökçe Melis Çolak

Doctor and researcher Kartal Dr. Lütfi Kırdar Şehir Hastanesi İstanbul
COVID-19
Open institution page
Suggest a correction

Is this your profile? Claim it and verify your details.

Claim profile

Person ↔ Disease

Which diseases does this doctor work on?

From source

Trust

Where does this information come from?

The source is stated next to each piece of information. If you see something wrong, you can suggest a correction.

  • SpecialtyInfectious Diseases and Clinical Microbiologysaglik.gov.trFrom source
  • Department name at the sourceEnfeksiyon Hastalıklarısaglik.gov.trFrom source
  • InstitutionKartal Dr. Lütfi Kırdar Şehir Hastanesisaglik.gov.trFrom source
  • Area of workCOVID-19Extracted from 5 publications · Model version —From source
  • Publications11 publicationsORCID, Europe PMCFrom source
  • ORCID0000-0001-9065-374XORCIDFrom source
  • Last synchronised5 November 2026 08:56https://lutfikirdareah.saglik.gov.tr/TR-1476160/doktorlarimiz.html#gokce-melis-colaksaglik.gov.tr

Scientific work

Publications on COVID-19

11 publications

  1. Missed Opportunities for HIV Testing in Hospitalised Adults in Türkiye: Indicator Conditions and Testing Coverage in a National Multicentre Point-Prevalence Survey (HIV-ICs-TR)

    Scientific Reports, 2026

    DOI 10.1038/s41598-026-54294-6 PMID 42218185 Open-access full textSource: ORCID

  2. Beyond the Usual Suspects: RSV Infection in Patients With Hematological Malignancies Compared to Influenza and SARS‐COV‐2—A Report From the EPICOVIDEHA/EPIRESEHA Registry

    American Journal of Hematology, 2025

    DOI 10.1002/ajh.70166 PMID 41439460 3 citations (Europe PMC) Open-access full textSource: ORCID

  3. Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey

    Infection, 2024

    DOI 10.1007/s15010-023-02169-7 PMID 38388854 8 citations (Europe PMC) Open-access full textSource: Europe PMC

  4. Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022

    eClinicalMedicine, 2024

    DOI 10.1016/j.eclinm.2024.102553 PMID 38533127 38 citations (Europe PMC) Open-access full textSource: ORCID

  5. Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA Registry

    Haematologica, 2024

    DOI 10.3324/haematol.2023.284678 PMID 38572549 11 citations (Europe PMC) Open-access full textSource: ORCID

  6. Survival in multiple myeloma and SARS‐COV‐2 infection through the COVID‐19 pandemic: Results from the EPICOVIDEHA registry

    Hematological Oncology, 2024

    DOI 10.1002/hon.3240 PMID 38050405 16 citations (Europe PMC) Open-access full textSource: ORCID

  7. Age, successive waves, immunization, and mortality in elderly COVID-19 hematological patients: EPICOVIDEHA findings

    International Journal of Infectious Diseases, 2023

    DOI 10.1016/j.ijid.2023.10.013 PMID 37863310 16 citations (Europe PMC) Open-access full textSource: ORCID

  8. Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry

    International Journal of Antimicrobial Agents, 2023

    DOI 10.1016/j.ijantimicag.2023.106952 PMID 37582478 12 citations (Europe PMC) Open-access full textSource: ORCID

  9. P1521: IMPROVED CLINICAL OUTCOME OF COVID-19 IN HAEMATOLOGIC MALIGNANCY PATIENTS RECEIVING A FOURTH DOSE OF ANTI-SARS-COV-2 VACCINE: AN EPICOVIDEHA REPORT

    HemaSphere, 2023

    DOI 10.1097/01.hs9.0000972964.65137.d1 Open-access full textSource: ORCID

  10. Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey

    Cancers, 2022

    DOI 10.3390/cancers14225530 PMID 36428621 10 citations (Europe PMC) Open-access full textSource: ORCID

View all 11 publications